Unlike conventional cancer drugs that attack and kill cancer cells directly, anti-cancer immunotherapy, which kills cancer cells by strengthening the body’s immunity, is a novel type of cancer treatment currently attracting increased attention.
Unfortunately, a minority of cancer patients who have some degree of pre-existing immunity only benefit from anti-cancer immunotherapy.
Recently, doxorubicin, a cancer treatment drug, has been shown to boost patients’ immune response by releasing components when cancer cells are killed.
However, as the toxicity and inflammatory responses induced by doxorubicin can affect normal cells in addition to cancer cells, it can lower patients’ immunity levels, which limits its effectiveness for immunotherapy.
In a new study from the Korea Institute of Science and Technology, researchers developed an anti-cancer prodrug that can improve anti-cancer immunotherapy by reacting only with cancer cells, thereby minimizing the toxicity to normal cells, including immune cells, and boosting patient immunity.
Previous research reported the development of an anti-cancer drug that targets cancer cells by suppressing the resistance to doxorubicin without reacting with normal cells.
In contrast, this research team developed a prodrug for anti-cancer immunotherapy that utilizes the immunity-boosting potential of doxorubicin.
The developed prodrug exhibits anticancer effects when activated by abundant enzymes present in cancer cells. As these enzymes are not present in normal cells, they do not experience toxicity and inflammatory responses.
The ability to target cancer cells exclusively increases patient immunity, inducing an active anticancer immune response when doxorubicin is activated in cancer cells.
The developed anti-cancer drug strongly improved the anti-cancer immune response in nonclinical animal models and reduced side effects associated with inflammatory responses and toxicity in normal tissues.
Therefore, the drug dosage can probably be increased to enhance its effectiveness for chemotherapy without causing notable side effects.
In addition, because the prodrug was developed by utilizing a drug already in clinical use, the commercialization process is expected to be relatively straightforward in terms of clinical trials and mass production.
If you care about cancer and your health, please read studies about doing this can increase death risk in breast cancer and findings of this common drug can improve survival in two cancers.
For more information about cancer prevention and treatment, please see recent studies about this new type of diabetes can be an early sign of pancreatic cancer and results showing that many common drugs for diabetes and inflammation may kill cancer.
The study is published in Biomaterials. One author of the study is Dr. Ju Hee Ryu.
Copyright © 2021 Knowridge Science Report. All rights reserved.
